Relative Contribution of Atrial Fibrillation to Outcomes of Patients With Cardiomyopathy Based on Severity of Left Ventricular Dysfunction.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 14 02 2023
revised: 22 03 2023
accepted: 14 04 2023
medline: 13 6 2023
pubmed: 14 5 2023
entrez: 14 5 2023
Statut: ppublish

Résumé

In patients with left ventricular (LV) dysfunction, the risk of death or heart failure hospitalizations (HFHs) increases with worsening ejection fraction (EF). Whether the relative contribution of atrial fibrillation (AF) to outcomes is more pronounced in patients with worse EF is not confirmed. The present study aimed to investigate the relative influence of AF on the outcome of cardiomyopathy patients by severity of LV dysfunction. In this observational study, data from 18,003 patients with EF ≤50% seen at a large academic institution between 2011 and 2017 were analyzed. Patients were stratified by EF quartiles (EF<25%, 25%≤EF<35%, 35%≤EF<40%, and EF≥40%, for quartiles 1, 2, 3, and 4, respectively). and followed to the end point of death or HFH. Outcomes of AF versus non-AF patients were compared within each EF quartile. During a median follow-up of 3.35 years, 8,037 patients (45%) died and 7,271 (40%) had at least 1 HFH. Rates of HFH and all-cause mortality increased as EF decreased. The hazard ratios (HRs) of death or HFH for AF versus non-AF patients increased steadily with increasing EF (HR of 1.22, 1.27, 1.45, 1.50 for quartiles 1, 2, 3, and 4, respectively, p = 0.045) driven primarily by the risk of HFH (HR of 1.26, 1.45, 1.59, 1.69 for quartiles 1, 2, 3, and 4, respectively, p = 0.045). In conclusion, in patients with LV dysfunction, the detrimental influence of AF on the risk of HFH is more pronounced in those with more preserved EF. Mitigation strategies for AF with the goal of decreasing HFH may be more impactful in patients with more preserved LV function.

Identifiants

pubmed: 37182255
pii: S0002-9149(23)00240-0
doi: 10.1016/j.amjcard.2023.04.033
pii:
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-13

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Saba has received research support from Abbott and Boston Scientific and reports receiving consultation payments from Boston Scientific and Medtronic. The remaining authors have no conflicts of interest to declare.

Auteurs

Mumammad Talha Ayub (MT)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Gautam Rangavajla (G)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Floyd Thoma (F)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Suresh Mulukutla (S)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Konstantinos Aronis (K)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Aditya Bhonsale (A)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Krishna Kancharla (K)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Andrew Voigt (A)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Alaa Shalaby (A)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Nathan Anthony Mark Estes (NAM)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Sandeep Jain (S)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Samir Saba (S)

The Heart and Vascular Institute at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: sabas@upmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH